Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 15/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 15/20 | 0.60 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.56 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26090331 | 0.88 | KDM4E (0.71) | AKR1C3AKR1C2KCNK2KCNK10KDM4E | |
| SCHEMBL6361641 | 0.83 | AKR1C3 (0.65) | AKR1C3AKR1C2KCNK2KCNK10MEN1 | |
| SCHEMBL4013508 | 0.81 | GAA (0.56) | KDM4EMEN1PKMKMT2ANPSR1 | |
| SCHEMBL17084899 | 0.81 | TRIM24 (0.51) | KDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL30981444 | 0.81 | TRIM24 (0.51) | KDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL5226002 | 0.80 | TDP1 (0.54) | KDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL30076369 | 0.80 | ALDH1A1 (0.47) | AKR1C3AKR1C2KDM4EMEN1KMT2A | |
| SCHEMBL1234368 | 0.80 | ALDH1A1 (0.47) | AKR1C3AKR1C2KDM4EMEN1KMT2A | |
| SCHEMBL30665941 | 0.79 | AKR1C3 (0.69) | AKR1C3AKR1C2KCNK2KCNK10 | |
| SCHEMBL10955174 | 0.79 | AKR1C3 (0.69) | AKR1C3AKR1C2KCNK2KCNK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| EP-1963283-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065662-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065662-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | TRPV1, TRPV3, TRPV5 | AKR1C3 1372/4885AKR1C2 1685/4885KCNK2 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.